Compare Ascendis Pharma A/S (ASND) vs CarMax, Inc (KMX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs CarMax, Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while CarMax, Inc trades at $53.68 (market cap $7.59B). The key difference: Ascendis Pharma A/S is far larger — about 2.3× CarMax, Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, CarMax, Inc nearer its low. Which is the better fit depends on your goals.
| ASND | KMX | |
|---|---|---|
Market Cap | $17.74B | $7.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $65.20 |
52-Week Low | $163.32 | $30.88 |
Enterprise Value | $18.11B | $26.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
CarMax (KMX) trades at $53.49, up 4.86% with a bullish technical signal. The stock shows mixed fundamentals with a P/E of 33.22 and net margin of 0.84%, though recent Q1 2026 earnings beat expectations. Revenue trends downward from $31.9B in 2022 to $26.4B in 2025, while net cash flow turned negative at -$290M. Analyst sentiment is cautious with 62.9% hold ratings and a $48.91 consensus target below current price. Recent news highlights a four-pillar turnaround strategy under new CEO Keith Barr.
KMX presents a speculative opportunity amid transition, with potential upside from execution of digital and cost initiatives. Key risks include margin pressure, high debt load ($18.1B long-term), and investigation concerns. Near-term resistance at $53, support at $49. Wall Street remains neutral pending clearer turnaround evidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
